Big Move For Allogene Therapeutics, Inc.

Allogene Therapeutics, Inc. (ALLO:NASDAQ) shot up at $2.04, representing a gain of 44.7%. On Fri, Feb 14, 2025, ALLO:NASDAQ hit a New 2-Week High of $2.04. The stock appeared on our News Catalysts scanner on Fri, Feb 14, 2025 at 11:41 AM in the 'AGREEMENT' category. From Fri, Jan 31, 2025, the stock recorded 30.00% Up Days and 27.27% Green Days

The stock spiked on Tue, Nov 26, 2024 at $2.77 with a volume of 5M+.

About Allogene Therapeutics, Inc. (ALLO:NASDAQ)

Allogene Therapeutics Inc is the United States-based clinical stage immuno-oncology company. It is mainly engaged in the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is involved in developing a pipeline of multiple allogeneic T cell product candidates utilizing validated gene editing and advanced proprietary cell manufacturing technologies. Its pipeline includes UCART19 which is developed for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL), as well as several preclinical allogeneic CAR T therapies.